🏆 Finalist — NIH Data Sharing Index (“S-Index”) Challenge

Pilot corpus: NIH-funded biomedical datasets. Any DOI can be scored on demand — network effects sharpen as coverage grows.

Distinct Role of TP53 Co-mutations in Different EGFR Subtypes Mediating the Response to EGFR Tyrosine Kinase Inhibitors in Non-Small Cell Lung Cancer

Clinical Lung Cancer(2025)10.1016/j.cllc.2025.04.007Source: DataRank Database

Distinct Role of TP53 Co-mutations in Different EGFR Subtypes Mediating the Response to EGFR Tyrosine Kinase Inhibitors in Non-Small Cell Lung Cancer is a research paper published in Clinical Lung Cancer (2025). On theSindex it has a DataRank of 0.312. It has been cited 7 times.

N/A

0.312DataRank · unranked

Scored on demand from live citation data

7 citations

Cite:

DataRank reads this dataset's downstream impact straight off the citation graph — no black box, no proprietary weighting. How is this computed?

›Methodology & internals

datarank_citation_only_1hop_v6· scope data_onlyMethodology

Pipeline:MetadataData-paper checkEnrichmentCitation networkScoring

Enrichment:Funding (15 grants)Impact (FWCI 5.23)OA: hybridTopics (56)IDs (PubMed, OpenAlex)SDGs (1)

FAIR Checklist

Context only (not used in score)

Findable (1/2)

Has DOI

Accessible (0/2)

Interoperable (0/2)

Reusable (0/3)

FAIR checklist signals are shown for context only and do not affect DataRank scoring.

Run a calibrated FAIR evaluation for this paper →

We only score data papers we can read in full — never from an abstract alone.

DataRank Breakdown

Base Score 100%Citation Network 0%

Base Score Contribution

0.312

From this paper's citation signal

Citation Network Contribution

0

Citation network not refreshed for this result

This paper's DataRank is currently driven only by its base citation score. Citation network data was not refreshed for this result.

Learn more about DataRank methodology →

Authors (20)

Yi Lao,Tongze Fu,Zhongpeng Xie,Yanxia Wang,Tiantian Yang

Live enrichment

PubMed:40382269 OpenAlex:https://openalex.org/W4409716857

National Natural Science Foundation of China

Grant: 81372501

National Natural Science Foundation of China

Grant: 81773299

National Natural Science Foundation of China

Grant: 82330065

National Natural Science Foundation of China

Grant: 30900650

National Natural Science Foundation of China

Grant: 31430030

National Natural Science Foundation of China

Grant: 81572260

Key Technologies Research and Development Program

Grant: 2017YFC1308800

Guangzhou Municipal Science and Technology Program key projects

Grant: 2021B1212040017

Guangzhou Municipal Science and Technology Program key projects

Grant: 2023B1111020005

Guangzhou Municipal Science and Technology Program key projects

Grant: 2018A050506036

Guangzhou Municipal Science and Technology Program key projects

Grant: 2023B03J0106

Guangzhou Municipal Science and Technology Program key projects

Grant: 20170402094

Guangzhou Municipal Science and Technology Program key projects

Grant: 2020B1515120032

Science and Technology Planning Project of Guangdong Province

National Key Research and Development Program of China

FWCI

5.23

Citation Percentile

1.0%

Citation Trend

2025

2026

hybridLicense: cc-by-nc-nd

journalhttps://www.clinical-lung-cancer.com/article/S1525-7304(25)00078-6/pdf

publisherhttps://www.clinical-lung-cancer.com/article/S1525-7304(25)00078-6/pdf

publisherhttps://api.elsevier.com/content/article/PII:S1525730425000786?httpAccept=text/xml

publisherhttps://api.elsevier.com/content/article/PII:S1525730425000786?httpAccept=text/plain

journalhttps://doi.org/10.1016/j.cllc.2025.04.007

Fields of Study

Lung Cancer Treatments and MutationsCancer Genomics and DiagnosticsColorectal Cancer Treatments and StudiesHumansCarcinoma, Non-Small-Cell LungLung NeoplasmsErbB ReceptorsProtein Kinase InhibitorsFemaleMaleTumor Suppressor Protein p53Retrospective StudiesMutationMiddle AgedAgedPrognosisAdultSurvival RateFollow-Up StudiesAged, 80 and overTyrosine Kinase Inhibitors

MeSH Terms

Tyrosine Kinase InhibitorsAdultAgedAged, 80 and overCarcinoma, Non-Small-Cell LungFemaleFollow-Up StudiesHumansLung NeoplasmsMaleMiddle AgedMutationPrognosisRetrospective StudiesSurvival RateTumor Suppressor Protein p53Protein Kinase InhibitorsErbB Receptors

Keywords

MedicineLung cancerCancer researchTyrosine kinaseProtein-Tyrosine KinasesGefitinibErlotinibCancerEpidermal growth factor receptorOncologyInternal medicineReceptorResistanceEGFRPrognosisNSCLCCo-mutations

Sustainable Development Goals

SDG 0: Good health and well-being